CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report)’s share price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.26 and traded as low as $0.2231. CytoDyn shares last traded at $0.2310, with a volume of 2,076,821 shares traded.
CytoDyn Stock Down 6.1%
The stock has a market capitalization of $296.04 million, a PE ratio of -7.70 and a beta of 1.14. The stock has a fifty day moving average of $0.26 and a 200-day moving average of $0.28.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last posted its quarterly earnings results on Friday, January 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter.
About CytoDyn
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Further Reading
- Five stocks we like better than CytoDyn
- New Copper-Rich “Kraken” Zone Discovered
- Silver Is the New Oil—And the World’s Running Dry
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
- Silver’s squeeze is tightening – opportunity forming
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
